Drug Profile
Research programme: peptide-based vaccines - PeptiVir
Alternative Names: PVI-1000Latest Information Update: 23 Mar 2023
Price :
$50
*
At a glance
- Originator PeptiVir
- Class Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 23 Mar 2023 Discontinued - Preclinical for Influenza virus infections (Prevention) in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (Parenteral)
- 19 Jul 2016 Preclinical development is ongoing in USA